Biota Pharmaceuticals said today it has sold its broad spectrum antibiotic program to a new subsidiary of Spero Therapeutics for an undisclosed price.
The deal will expand Spero’s pipeline of candidates for bacterial infections, while...
NEW YORK CITY (dpa-AFX) - Biota Pharmaceuticals Inc. (BOTA) phase I multiple
ascending dose trial of BTA585 for the treatment and prevention of respiratory
syncytial virus infections, usually called RSV, has yielded positive results.
FOSTER CITY (dpa-AFX) - Biota Pharmaceuticals Inc.'s (BOTA) antiviral
compound, BTA585, has been granted Fast Track designation by FDA for the
treatment of respiratory syncytial virus infections in infants, young children
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Biota Holdings (BTA-AU):